52057-89-3 Usage
General Description
5-Isobutyl-[1,3,4]thiadiazol-2-ylamine is a chemical compound with the molecular formula C8H13N3S. It is a member of the thiadiazole family, which is known for its diverse range of biological activities. 5-ISOBUTYL-[1,3,4]THIADIAZOL-2-YLAMINE has been studied for its potential pharmaceutical applications, particularly in the field of medicinal chemistry. It is also used as a building block in organic synthesis for the preparation of various derivatives with potential biological activities. Additionally, 5-isobutyl-[1,3,4]thiadiazol-2-ylamine may have potential applications in the development of new agrochemicals and materials science. Its unique structure and properties make it a promising candidate for further research and development in various scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 52057-89-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,0,5 and 7 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 52057-89:
(7*5)+(6*2)+(5*0)+(4*5)+(3*7)+(2*8)+(1*9)=113
113 % 10 = 3
So 52057-89-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H11N3S/c1-4(2)3-5-8-9-6(7)10-5/h4H,3H2,1-2H3,(H2,7,9)
52057-89-3Relevant articles and documents
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides
Pryde, David C.,Maw, Graham N.,Planken, Simon,Platts, Michelle Y.,Sanderson, Vivienne,Corless, Martin,Stobie, Alan,Barber, Christopher G.,Russell, Rachel,Foster, Laura,Barker, Laura,Wayman, Christopher,Van Der Graaf, Piet,Stacey, Peter,Morren, Debbie,Kohl, Christopher,Beaumont, Kevin,Coggon, Sara,Tute, Michael
, p. 4409 - 4424 (2007/10/03)
Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.
